Cell

Changes in Alzheimer's treatments: from targeting amyloid protein to targeting tau protein

Updated

Abstract

Emerging tau-targeting therapies for Alzheimer's disease may slow tau accumulation and show early cognitive benefits.

  • PET scans suggest that tau-targeting treatments can slow down the buildup of tau protein in the brain.
  • Recent progress in therapies targeting amyloid β (Aβ) has helped improve future tau trial designs.
  • Lessons learned from earlier tau immunotherapies are contributing to initial successes in current tau trials.
  • Translating clinical results back into fundamental understanding of tau biology is critical for future developments.
  • Challenges remain in developing effective combination therapies and exploring targets beyond Aβ and tau.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of interests G.U.H. participated in industry-sponsored research projects from AbbVie, Biogen, Biohaven, Novartis, Roche, Sanofi, and UCB; received research support from GE Health; has ongoing research collaborations with Roche, UCB, AbbVie, and Ferrer; served as a consultant for AbbVie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, and UCB; and received honoraria for scientific presentations from AbbVie, Bayer, Bial, Biogen, Bristol Myers Squibb, Esteve, Kyowa Kirin, Pfizer, Roche, Teva, UCB, and Zambon. His institution received research support from AbbVie. H.Z. has served on scientific advisory boards and/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD; is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; and is a shareholder of CERimmune Therapeutics (outside the submitted work). J.-P.C. is one of the inventors of bepranemab and a stock owner of Discoveric bio alpha.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free